0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > NKG2A & CD94

NKG2A & CD94

Brief Information

Name:NK cell lectin-like receptor subfamily C member 1
Target Synonym:CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

NC4-C82F7-ELISA
 NKG2A & CD94 ELISA

Immobilized Anti-NKG2A Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus NKG2A&CD94, Fc,Avitag (Cat. No. NC4-C82F7) with a linear range of 0.1-16 ng/mL (QC tested).

NC4-R5258-MALS-HPLC
NKG2A & CD94 MALS images

The purity of Rat NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (Cat. No. NC4-R5258) is more than 90% and the molecular weight of this protein is around 145-160 kDa verified by SEC-MALS.

Synonym Name

NKG2A & CD94

Background

CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Monalizumab NN-8765; IPH-2201; NNC-0141-0000-0100 Phase 3 Clinical Innate Pharma, Novo Nordisk A/S Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Mouth Neoplasms; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Inflammation; Head and Neck Neoplasms; Genital Neoplasms, Female; Breast Neoplasms; Arthritis, Rheumatoid; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Hematologic Neoplasms Details
BMS-986315 BMS-986315 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Carcinoma, Non-Small-Cell Lung Details
S-095029 S-095029 Phase 2 Clinical Institut De Recherches Internationales Servier Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung Details
BRY-805 BRY805; BRY-805 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours Details
HY000102 HY-0102; HY-000102 Phase 1 Clinical Shanghai HyaMab Biotech Co Ltd Solid tumours Details
Monalizumab NN-8765; IPH-2201; NNC-0141-0000-0100 Phase 3 Clinical Innate Pharma, Novo Nordisk A/S Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Mouth Neoplasms; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Inflammation; Head and Neck Neoplasms; Genital Neoplasms, Female; Breast Neoplasms; Arthritis, Rheumatoid; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Hematologic Neoplasms Details
BMS-986315 BMS-986315 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Carcinoma, Non-Small-Cell Lung Details
S-095029 S-095029 Phase 2 Clinical Institut De Recherches Internationales Servier Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung Details
BRY-805 BRY805; BRY-805 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours Details
HY000102 HY-0102; HY-000102 Phase 1 Clinical Shanghai HyaMab Biotech Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje